Data Completeness England and Wales 2013

Date first seen = 2013 (excluding mesothelioma). Date of extract = 04/07/2014 (England) and 15/07/2014 (Wales)

eness for key fi	fields Eng	land and Wales														
	xpected number	Actual number	MDT Completeness (%)	CT Scan Field Completed (%)	Bronchoscopy Field Completed (%)	PS0-1 NSCLC Stage IA, IB, IIA or IIB	% PS0-1 NSCLC Stage IA, IB, IIA or IIB having FEV1 absolute and % predicted	Data Completeness Seen by Nurse Specialist (%)	Completeness	Performance Status Completeness (%)	Stage Completeness (%)	PS and Stage Completeness (%)	Number of patients where Co-morbidity precluded treatment	Comorbidity recorded where Co-morbidity precluded treatment (%)	Treatment Recorded (%)	Organisational Audi Participation (%
1,53	35	1,692	99.9	99.8	99.8	230	65.7 🛕	88.9	88.8	91.5	94.5	88.5	35	17.1 🔺	91.7	50.0
428	28	385	100.0	100.0	100.0	66	86.4	99.5	99.5 •	99.5	98.2	98.2	5	40.0 🛕	95.1	
119	19	256	100.0	100.0	100.0	37	51.4 🛕	96.9	96.9	96.5	98.4	96.1	1	100.0	91.4	
22		265	100.0	99.6	99.6	33	63.6	96.6	96.6	90.2	97.4	87.5	1	0.0	94.0	
323		315	100.0	99.4	99.4	51	90.2	85.1	85.1	96.5	98.4	96.2	0	N/A	88.9	
12		142	100.0	100.0	100.0	13	53.8	73.9 🛕	73.9 🛕	62.0	87.3	58.5	3	33.3 🛕	85.2	
	82	147	99.3	99.3	99.3	14	0.0	85.0	85.0	83.0 🛕	86.4	77.6	15	0.0	94.6	
193	93	177	100.0	100.0	100.0	16	6.3	66.1	65.5 🛕	92.1	83.1 🛕	78.5	10	20.0	89.3	
1,92	23	2,348	97.4	98.6	86.4	286	81.8	92.9	83.4 🛕	86.8	85.9	77.3 🛕	208	94.2	91.3	62.
62	62	134	100.0	100.0	97.8	18	72.2 🛕	97.0	69.4 🛕	86.6	66.4	58.2	0	N/A	84.3 🛕	
170	70	252	96.0	98.0	98.4	32	90.6	98.4	98.4 •	94.4	98.4	94.4	171	99.4	94.0	
140	46	195	100.0	100.0	100.0	26	57.7 🛕	97.9	97.9	97.4	94.9	94.4	10	0.0	98.5	
142	42	167	100.0	100.0	99.4	21	95.2	97.6	88.0	99.4	98.8	98.2	0	N/A	97.0	
257	257	325	96.9	97.8	69.2	58	98.3	99.7	99.7	87.7	96.3	84.9 🔺	4	75.0 🛕	92.9	
349		350	88.9 🛕	94.0	56.6	32	87.5	85.4	85.1	67.7	58.9 🛕	44.3 🛕	22	100.0	93.4	
46		490	99.8	100.0	94.5	39	92.3	81.4	48.0 🛕	87.1	90.2	79.6	0	N/A	83.7	4
332	332	433	100.0	100.0	92.4	60	60.0	98.2	97.2 •	87.3	84.5	76.4	1	100.0	92.1	
d 2,578	78	2,885	97.5	91.0	87.1	393	60.3 🛕	89.5	88.4 •	91.8	87.7	84.0 🛕	198	92.4	89.4	70.
192	92	221	99.5	98.2	97.3	21	95.2	91.9	84.6	97.3	98.2	96.8	73	100.0	95.0	
57	57	99 •	98.0	100.0	98.0	16	75.0	79.8 🛕	78.8 🛕	84.8 🛕	92.9	80.8	2	100.0	92.9	4
109	09	131	93.9 🔺	97.7	87.0	8	87.5	69.5 🔺	67.9 🛕	75.6	80.2 🛕	69.5 🔺	0	N/A	71.8 🛕	
112		142	100.0	99.3	98.6	24	37.5 🛕	84.5 🛕	84.5 🛕	98.6	94.4	93.7	1	0.0	77.5 🛕	
	76	198	100.0	100.0	99.5	27	92.6	100.0	98.5	99.5	99.5	99.0	15	100.0	91.4	
	76	255	100.0	100.0	100.0	29	96.6	100.0	100.0	100.0	100.0	100.0	35	100.0	100.0	
	261	23 •	91.3	91.3	87.0	11 •	63.6	87.0	87.0	91.3 •	100.0	91.3 •	5 •	100.0	82.6	
108		171 • 146 •	99.4	99.4	95.9	19	78.9	90.6	89.5	95.9	83.0 🛕	80.1	0	0.0	98.2 • 89.7 •	
17		179	95.2 • 100.0 •	84.9 A 100.0	83.6 1 00.0	26 24	0.0 A 95.8 •	73.3 A 100.0	72.6 A 98.3 •	81.5 A 94.4 •	80.1 A 99.4	78.1 △ 94.4 •	2	N/A 0.0 🛕	87.7	
	52	160	99.4	100.0	98.8	28	0.0	71.9	71.9	96.9	97.5	94.4	47	78.7	91.3	
103		178	100.0	96.1	99.4	43	97.7	94.9	94.9	97.2	98.9	97.2	14	100.0	86.0	
338		342	96.8	99.1	88.6	48	27.1	100.0	100.0	75.7	80.7	68.4	0	N/A	93.0	
134	34	175	100.0	100.0	100.0	24	87.5	64.0 🛕	64.0 🛕	100.0	98.9	98.9	3	66.7	87.4	
3!	35	66	100.0	100.0	98.5	12	41.7 🛕	75.8 🛕	75.8 🛕	100.0	100.0	100.0	0	N/A	84.8 🛕	
217	17	186	82.3	0.0	0.0	6	100.0	98.4	96.2 •	83.3 🛕	18.8 🛕	18.3 🛕	0	N/A	78.5 🛕	
200	206	213	97.7	85.9	62.0	27	14.8 🛕	95.8	95.3 •	94.4	87.8	85.0 🛕	0	N/A	89.7	
r 1,51	12	1,446	98.9	98.6	98.1	195	68.2	93.6	92.4	91.6	98.2	91.1	201	92.0	91.3	72.7
11!		122	99.2	100.0	97.5	11	9.1	90.2	85.2	86.1	97.5	86.1	11	100.0	87.7	
110		121	98.3	100.0	100.0	15	100.0	95.0	91.7 •	78.5 🛕	95.9	78.5	22	100.0	95.9	
11!	15	72	98.6	97.2	94.4	7	0.0	91.7	91.7 •	90.3	100.0	90.3	8	100.0	88.9	
86	86	103	100.0	100.0	100.0	22	95.5	100.0	99.0 •	100.0	100.0	100.0	22	100.0	100.0	
84	84	90	97.8	97.8	98.9	9	100.0	98.9	98.9 •	96.7	96.7	94.4	37	100.0	97.8	
340	340	280	100.0	100.0	100.0	30	26.7 🛕	83.2 🛕	83.2 🛕	81.4 🛕	98.9	80.7 🛕	17	41.2	77.5 🛕	
	98	92 •	100.0	98.9	93.5	14	85.7	90.2	87.0	98.9	97.8	96.7	13	100.0	91.3	
113		158	99.4	99.4	98.7	17	35.3 🛕	99.4	99.4 •	99.4	99.4	99.4	23	73.9 🛕	97.5	
	00	92	100.0	100.0	100.0	18	100.0	98.9	98.9 •	97.8	100.0	97.8	18	100.0	94.6	
	39	131	100.0	100.0	100.0	33	78.8	100.0	98.5 •	99.2	100.0	99.2	7	100.0	99.2	
	12	183	95.6	92.9	94.0	19	89.5	95.1	94.5	95.1	95.6	94.0	23	100.0	92.3	

Key

Tertiary Trust

Table 1a																
Data completenes	Expected number		MDT Completeness (%)		Bronchoscopy Field Completed (%)	PS0-1 NSCLC Stage IA, IB, IIA or IIB	% PS0-1 NSCLC Stage IA, IB, IIA or IIB having FEV1 absolute and % predicted	Data Completeness Seen by Nurse Specialist (%)	Data Completeness Nurse Specialist present at Diagnosis (%)	Performance Status Completeness (%)	Stage Completeness (%)	PS and Stage Completeness (%)	Number of patients where Co-morbidity precluded treatment	Comorbidity recorded where Co-morbidity precluded treatment (%)	Treatment Recorded (%)	Organisational Audit Participation (%)
London Cancer Alliance	2,520	2,006	95.2	86.2	77.4	219	61.6	86.6	80.8	83.8	92.9	81.5 🛕	148	93.2	87.9	31.3
RAS	100	124	94.4	93.5	81.5	11	100.0	88.7	86.3	87.9	92.7	84.7 🛕	34	100.0	90.3	A
RAX	159	122	99.2	100.0	95.1	15	93.3	100.0	93.4	74.6	94.3	73.8	2	100.0	99.2	A
RC3	75	65 •	98.5	98.5	89.2	5	60.0 🛕	98.5	95.4	96.9	90.8	89.2	2	100.0	100.0	A
RFW	70	94 •	100.0	100.0	100.0	8	100.0	6.4	5.3 🛕	93.6	96.8	93.6	2	100.0	84.0 🔺	A
RJ1	273	111 🔺	100.0	100.0	100.0	15	0.0	100.0	87.4	75.7 🛕	99.1	74.8 🛕	8	100.0	100.0	<u> </u>
RJ2	116	304	98.0	34.2	34.2	17	29.4	88.2	82.2 🛕	65.5	90.8	61.2	0	N/A	89.8	•
RJ6	132	121	95.9	98.3	70.2	14	71.4 🛕	100.0	100.0	90.1	98.3	89.3	30	86.7	97.5	•
RJ7	239	136	94.9	89.0	86.8	32	81.3	55.1 🛕	49.3	91.2	86.0	83.1 🛕	0	N/A	68.4	•
RJZ	114	137	100.0	99.3	98.5	10	100.0	100.0	100.0	100.0	99.3	99.3	1	100.0	76.6	•
RQM	80	72	95.8	97.2	91.7	9	33.3	93.1	93.1	95.8	95.8	93.1	1	0.0	87.5	<u> </u>
RT3 •	148 •	23 •	26.1	78.3	21.7 •	0 •	0.0	91.3 ♦	82.6	21.7 •	65.2	21.7	0 •	N/A •	87.0	<u> </u>
RV8	100	94	96.8	94.7	97.9	12	91.7	96.8	94.7	94.7	98.9	94.7	11	100.0	91.5	
RVR	245 289	181 2 49 •	79.0	83.4	53.6 A 99.6 •	9 51	77.8	86.7 • 87.1 •	55.8 A 87.1 •	56.9	76.8	54.7 A 98.4 •	9 4	100.0 •	64.1 A 95.6 •	<u> </u>
RYJ RYQ	370	170	100.0 • 95.9 •	100.0 • 95.3 •	70.6	11	51.0 A 9.1 A	98.8	97.6	100.0 • 94.7 •	98.4 • 95.3 •	94.7	43	93.0	94.1	<u> </u>
KIQ	370	170	75.7	75.5	70.6	11	7.1	70.0	97.0	74.7	75.5	74.7	43	73.0	74.1	_
Manchester, Lancs and S Cumbria	3,173	3,373	99.8	99.8	98.7	509	55.6	86.3 •	85.7	89.1	95.5	86.8	52	55.8 🛕	92.5	57.1
RBT	120	189	100.0	100.0	100.0	28	0.0	99.5	99.5	98.9	95.8	94.7	6	66.7	94.7	•
RJN	108	127	100.0	100.0	100.0	20	80.0	99.2	99.2	100.0	96.9	96.9	1	100.0	96.9	•
RM2 ◆	236 🔷	194 🔷	99.5 🔷	99.5 🔷	99.0 ♦	47 🔷	89.4 🔷	83.5 ♦	83.5 ◆	91.8 ♦	97.9 ♦	90.2 🔷	8 🔷	100.0 ◆	99.0 ♦	•
RM3	220	193	100.0	99.5	100.0	28	96.4	97.4	95.9	97.9	98.4	97.4	3	0.0	97.4	<u> </u>
RMC	220	213	99.5	100.0	94.8	32	93.8	93.0	93.0	89.2	92.0	82.6	1	100.0	94.4	<u> </u>
RMP	150	165	100.0	100.0	100.0	8	25.0 🛕	95.8	95.8	69.1	93.3	67.3 🛕	5	20.0 🛕	93.9	A
RRF	200	247	100.0	100.0	100.0	33	87.9	84.6	84.6	95.1	98.0	93.9	0	N/A	86.2	•
RTX	184	151	100.0	99.3	98.0	25	48.0 🛕	23.8 🛕	20.5 🛕	77.5 🛕	92.1	74.2 🛕	0	N/A	91.4	•
RW3	212	212	98.6	98.6	97.6	37	91.9	95.8	95.3	96.7	97.6	95.3	13	84.6	91.5	•
RW6	573	634	100.0	100.0	100.0	93	0.0	79.2	79.2	77.9	91.5	74.0 🛕	0	N/A	94.0	
RWJ	145	213	99.5	99.5	99.5	29	41.4	86.4	86.4	93.9	97.2	93.4	3	66.7	73.2	•
RXL	242	240	100.0	100.0	92.1	35	68.6	100.0	97.9	100.0	100.0	100.0	10	10.0	100.0	
RXN RXR	136 427	240 • 355 •	100.0	100.0	98.3	39 55	25.6 A 81.8 •	88.3 • 85.6 •	87.5 • 85.1 •	77.5 A 96.3 •	91.3 • 99.7 •	75.0 A 96.1 •	0	0.0 A	94.6 • 89.6 •	•
NAN.	427	333	100.0	100.0	100.0	33	01.0	05.0	63.1	70.3	77.7	70.1	0	IN/A	07.0	
Northern England	2,134	2,615	99.8	99.6	100.0	374	85.8	99.7	99.2	99.5	98.2	97.7	124	59.7	96.9	77.8
RE9	134	135	100.0	100.0	100.0	16	87.5	100.0	100.0	99.3	100.0	99.3	2	0.0	99.3	•
RLN	226	264	100.0	100.0	100.0	37	86.5	100.0	100.0	98.5	96.2	94.7	37	43.2	94.7	
RNL	170	235	100.0	100.0	100.0	24	95.8	100.0	100.0	97.4	98.7	96.2	8	87.5	95.7	A
RR7	132	217	97.2	100.0	100.0	36	63.9 🛕	99.1	97.7	100.0	89.9	89.9	7	100.0	97.2	•
RTD	166	345	100.0	100.0	100.0	58	84.5	100.0	97.7	100.0	100.0	100.0	8	100.0	98.3	•
RTF	364	358	100.0	100.0	100.0	53	73.6 🛕	100.0	99.7	100.0	98.6	98.6	30	100.0	97.5	•
RTR	270	351	100.0	100.0	100.0	47	89.4	100.0	100.0	100.0	100.0	100.0	1	100.0	93.7	A
RVW	300	297	100.0	100.0	100.0	40	97.5	100.0	100.0	99.7	98.7	98.3	31	16.1 🔺	99.7	•
RXP	372	413	100.0	97.3	99.8	63	95.2	98.8	98.1	99.8	99.5	99.3	0	N/A	97.1	•

Table 1a Data completenes	s for key fields En	ngland and Wales														
Code	Expected number	Actual number	MDT Completeness (%)	CT Scan Field Completed (%)	Bronchoscopy Field Completed (%)	PS0-1 NSCLC Stage IA, IB, IIA or IIB	% PS0-1 NSCLC Stage IA, IB, IIA or IIB having FEV1 absolute and % predicted	Data Completeness Seen by Nurse Specialist (%)	Data Completeness Nurse Specialist present at Diagnosis (%)	Performance Status Completeness (%)	Stage Completeness (%)	PS and Stage Completeness (%)	Number of patients where Co-morbidity precluded treatment	Comorbidity recorded where Co-morbidity precluded treatment (%)	Treatment Recorded (%)	Organisational Audit Participation (%)
South East Coast	2,191	2,389	99.1	99.8	99.5	300	43.0 🛕	90.3	82.3	92.9	95.9	90.5	42	59.5 🛕	88.8	58.3
RA2	109	97 •	100.0	100.0	100.0	14	78.6	100.0	99.0	66.0 🛕	66.0 🛕	49.5	0	N/A	88.7	<u> </u>
RDU	116	196	99.5	100.0	99.5	30	56.7 🛕	96.4	95.9	99.5	98.0	98.0	1	100.0	98.5	A
RN7	121	136	100.0	99.3	100.0	23	95.7	100.0	94.9 •	100.0	95.6	95.6	0	N/A	95.6	•
RPA	205	182	98.4	100.0	100.0	17	11.8 🛕	100.0	100.0	98.9	98.4	97.3	0	N/A	67.0 🛕	•
RTK	159	129	100.0	100.0	100.0	16	81.3	35.7 🛕	34.9 🛕	100.0	100.0	100.0	0	N/A	62.0 🔺	A
RTP	156	168	98.2	99.4	98.2	19	78.9	95.8	95.8	92.9	98.8	92.3	17	52.9 🛕	89.3	•
RVV	374	456	97.6	100.0	100.0	49	0.0	99.8	60.5 🛕	80.0	95.0	77.4	0	N/A	86.8	•
RWF	203	227	99.6	99.6	99.6	37	0.0	99.6	99.6	99.6	99.6	99.6	0	N/A	92.1	•
RXC	229	268	100.0	100.0	100.0	36	77.8	82.8	82.8 🛕	96.6	96.6	94.0	3	33.3 🛕	96.6	•
RXH	251	230	99.6	99.6	99.6	24	12.5 🛕	73.0 🛕	73.0 🛕	95.7	96.1	93.5	10	50.0	94.3	•
RYR16	128	139	100.0	100.0	96.4	18	100.0	100.0	99.3 •	99.3	98.6	97.8	6	100.0	92.1	
RYR18	140	161	99.4	100.0	100.0	17	0.0	84.5	84.5 🛕	94.4	96.3	93.2	5	60.0	93.8	<u> </u>
South West	2,007	2,173	99.8	99.8	99.5	302	58.3	91.5	90.9	91.9	93.1	88.0	57	87.7	93.9	83.3
RA3	82	98	100.0	100.0	100.0	6	83.3	69.4	69.4	74.5	81.6	69.4	6	50.0	92.9	•
RA4	62	82	100.0	100.0	100.0	13	0.0 🛕	92.7	92.7	96.3	73.2	70.7	0	N/A	96.3	•
RA7	180	140	100.0	100.0	100.0	29	48.3 🛕	76.4	76.4 🛕	95.7	94.3	93.6	0	N/A	97.9	A
RA9	156	201	100.0	100.0	98.5	22	90.9	100.0	96.5 •	83.1 🛕	99.0	82.1 🔺	12	91.7	94.5	•
RBA	121	165	100.0	100.0	100.0	25	24.0 🛕	93.3	93.3 •	88.5	85.5	81.8 🛕	0	N/A	98.8	•
RBZ	85	78 •	100.0	100.0	100.0	5	60.0 🛕	92.3	92.3	64.1	76.9 🛕	55.1 🛕	0	N/A	93.6	
RD1	170	200	100.0	100.0	100.0	29	0.0	99.5	99.5	96.5	92.5	89.5	1	0.0	92.0	•
REF	223	238	100.0	100.0	100.0	35	82.9	100.0	100.0	99.2	100.0	99.2	0	N/A	97.9	•
RH8	200	195	100.0	100.0	98.5	40	92.5	100.0	99.0	99.5	100.0	99.5	32	100.0	94.9	•
RK9	256	282	100.0	100.0	100.0	31	100.0	77.0 🛕	77.0 🛕	89.7	91.8	84.8 🛕	6	66.7 🛕	89.0	•
RTE	244	282	98.6	98.6	98.2	40	15.0 🛕	98.2	97.2 •	96.5	94.7	94.0	0	N/A	90.4	A
RVJ	228	210	100.0	100.0	100.0	27	92.6	86.7	86.7	95.2	97.6	94.3	0	N/A	95.2	•
Thames Valley	1,031	1,054	99.2	93.0	68.7 ▲	185	68.1 🛕	95.8	95.4	95.4	93.1	89.2	15	73.3 🛕	93.2	83.3
RD7	112	142	98.6	98.6	98.6	14	28.6 🛕	94.4	93.7 •	87.3	93.7	83.1 🛕	0	N/A	93.0	•
RD8	96	86	100.0	100.0	100.0	13	0.0	90.7	88.4 •	98.8	52.3 🛕	52.3 🛕	0	N/A	83.7 🛕	A
RHW	206	180	100.0	100.0	98.3	23	95.7	95.6	95.6	96.1	100.0	96.1	8	100.0	97.8	•
RN3	113	151	98.0	100.0	98.0	22	90.9	100.0	100.0	97.4	92.1	90.1	4	50.0 🛕	92.7	•
RTH	303	317	99.7	77.9 p	3.8	84	69.0 🛕	94.3	94.3 •	95.3	97.2	92.7	2	0.0	92.4	•
RXQ	201	178	98.9	98.9	90.4	29	75.9	98.9	98.3 •	97.8	98.9	97.8	1	100.0	94.9	•
Wessex	1,366	1,326	99.4	98.9	82.2	199	78.9	92.0	90.3	95.2	96.2	92.5	24	37.5	92.8	77.8
R1F	95	92	100.0	100.0	100.0	12	100.0	100.0	100.0	100.0	100.0	100.0	4	100.0	92.4	77.0
RBD	82	107	100.0	100.0	100.0	21	85.7	99.1	94.4	99.1	98.1	97.2	2	0.0	91.6	•
RD3	150	140	98.6	98.6	97.9	17	52.9	94.3	94.3	97.1	93.6	92.1	5	20.0	91.4	
RDZ	170	183	99.5	99.5	96.7	23	82.6	97.8	94.5	81.4	90.7	76.5	6	16.7	92.9	•
RHM	278	221	99.1	99.5	96.8	41	85.4	70.1	69.7	99.5	99.5	99.5	0	N/A	94.1	•
RHU	300	346	99.7	97.1	36.4	47	87.2	98.8	96.2	97.7	96.0	93.9	0	N/A	90.8	•
RN506	85	82	100.0	100.0	100.0	11	36.4	74.4	74.4	84.1	92.7	79.3	4	0.0	91.5	<u> </u>
RN541	105	80	97.5	98.8	100.0	12	58.3	97.5	95.0	97.5	98.8	96.3	1	100.0	97.5	•
RNZ	101	75	100.0	100.0	100.0	15	80.0	100.0	100.0	100.0	100.0	100.0	2	100.0	98.7	•

	number	Actual number	MDT Completeness (%)	CT Scan Field Completed (%)	Bronchoscopy Field Completed (%)	PS0-1 NSCLC Stage IA, IB, IIA or IIB	% PS0-1 NSCLC Stage IA, IB, IIA or IIB having FEV1 absolute and % predicted	Data Completeness Seen by Nurse Specialist (%)	Data Completeness Nurse Specialist present at Diagnosis (%)	Performance Status Completeness (%)	Stage Completeness (%)	PS and Stage Completeness (%)	Number of patients where Co-morbidity precluded treatment	Comorbidity recorded where Co-morbidity precluded treatment (%)	Treatment Recorded (%)	Organisational Audi Participation (%
West Midlands	2,778	3,202	99.7	99.3	92.3	390	67.7	95.4	94.9	93.2	91.3	87.5	61	50.8	90.6	66.
RBK	158	151	100.0	99.3	94.7	19	68.4 🛕	98.7	98.7 •	99.3	99.3	99.3	5	40.0 🛕	99.3	
RJC	5	88 •	100.0	100.0	100.0	9	66.7 🛕	93.2	93.2	88.6	90.9	86.4	12	66.7 🛕	93.2	
RJD	160	148	100.0	100.0	100.0	16	87.5	98.6	98.6	100.0	95.3	95.3	4	25.0 🛕	94.6	
RJE	310	349	100.0	100.0	100.0	28	0.0	96.8	96.8	76.2	78.5 🛕	61.6	1	0.0	92.0	
RKB	249	234	100.0	99.1	100.0	29	100.0	99.1	99.1	100.0	96.2	96.2	0	N/A	99.1	
RL4	205	237	100.0	100.0	100.0	32	90.6	100.0	100.0	99.6	96.2	96.2	4	0.0	90.7	
RLQ	74	129	100.0	98.4	97.7	18	72.2 🛕	99.2	96.9	96.9	96.1	93.8	0	N/A	95.3	
RLT	96	110	100.0	99.1	98.2	10	100.0	95.5	93.6	99.1	92.7	91.8	5	40.0 🛕	86.4	
RNA	180	223	100.0	100.0	100.0	13	7.7 🛕	91.9	91.9 •	68.2	57.4	43.9 🛕	2	50.0	91.9	
RR1	404	496	98.0	97.0	55.0	61	93.4	96.4	94.8	97.2	96.2	95.6	2	50.0 🛕	87.7	
RRK	245	253	100.0	100.0	99.6	50	92.0	95.7	95.7 •	100.0	99.6	99.6	9	22.2	93.3	
RWP	161	210	100.0	100.0	100.0	27	77.8	98.6	98.6	98.6	97.6	97.1	0	N/A	91.9	
RWP01	64	73	100.0	100.0	98.6	6	33.3 🛕	95.9	95.9	86.3	91.8	80.8 p	0	N/A	98.6	
RXK	259	244	99.6	99.2	96.7	31	74.2 🛕	97.1	96.7 •	97.1	95.1	94.3	17	82.4	85.2	
RXW	208	256	100.0	100.0	100.0	41	0.0	77.0 🛕	77.0 🛕	94.5	93.4	89.1	0	N/A	75.4	
Yorkshire and	3,810	3.994	99.6	99.9	98.2	603	59.9	96.1	95.4	97.8	94.1	92.3	293	89.4	93.5	66.7
the Humber	,															
RAE	240	218	100.0	100.0	100.0	36	55.6	100.0	100.0	100.0	92.7	92.7	0	N/A	91.7	
RCB55	173	175	98.9	100.0	100.0	31	93.5	100.0	93.1 •	98.9	86.9	86.9	0	N/A	92.6	
RCBCA	126	137	99.3	100.0	100.0	11	81.8	100.0	90.5	97.8	94.2	92.7	0	N/A	99.3	
RCD	91	100	99.0	99.0	99.0	9	88.9	99.0	97.0	99.0	100.0	99.0	10	100.0	93.0	
RCF	118	131	100.0	100.0	100.0	19	100.0	100.0	100.0	100.0	100.0	100.0	1	0.0	100.0	
RFF	131	163	100.0	100.0	98.2	20	70.0 🛕	98.2	97.5	99.4	89.6	89.6	18	11.1	98.2	
RFR	144	230	100.0	100.0	100.0	37	100.0	100.0	100.0	100.0	100.0	100.0	0	N/A	87.8	
RFS	174	186	100.0	99.5	65.1	25	68.0 🛕	100.0	100.0	96.8	96.2	93.5	0	N/A	98.9	
RHQ	480	435	100.0	100.0	100.0	63	92.1	84.8 🛕	84.8 🛕	100.0	99.1	99.1	118	100.0	88.5	
RJL	226	333	100.0	100.0	100.0	67	68.7 🛕	98.2	98.2 •	97.6	99.1	96.7	25	92.0	94.6	
RP5	317	288	100.0	100.0	100.0	38	76.3	99.7	99.7 •	100.0	91.7	91.7	0	N/A	95.5	
RR8	565	509	99.4	100.0	100.0	87	14.9 🛕	100.0	100.0	99.4	96.9	96.5	0	N/A	94.3	
RWA	401	369	100.0	100.0	100.0	67	9.0 🛕	79.9 🛕	79.9 🛕	90.8	90.5	83.2 🛕	118	91.5	96.5	
RWY	244	277	99.6	100.0	100.0	36	75.0	100.0	100.0	100.0	76.2 🛕	76.2 🛕	1	100.0	94.6	
RXF	380	443	98.6	99.8	99.8	57	50.9 🛕	99.3	99.3	93.7	96.2	90.5	2	0.0	89.2	<u> </u>
England Total	28,558	30,503	98.9	97.6	93.0	4,185	64.7	92.3	90.0	92.5	93.3	88.2	1,458	82.2	91.9	62.

Code		Actual number	MDT	CT Scan Field	Bronchoscopy		% PS0-1 NSCLC	Data	Data	Performance	Stage	PS and Stage	Number of	Comorbidity	Treatment	Organisational Aug
	number		Completeness (%)	Completed (%)	Field Completed (%)	Stage IA, IB, IIA or IIB	Stage IA, IB, IIA or IIB having FEV1 absolute and % predicted	Completeness Seen by Nurse Specialist (%)	Completeness Nurse Specialist present at Diagnosis (%)	Status Completeness (%)	Completeness (%)	Completeness (%)	patients where Co-morbidity precluded treatment	recorded where Co-morbidity precluded treatment (%)	Recorded (%)	Participation (9
North Wales	459	487	100.0	96.3	45.6	66	84.8	95.7 •	N/A	96.7	98.2	95.3	N/A	N/A	94.3	33
7A1A1	184	175	100.0	94.9	38.9	26	100.0	96.0	N/A	96.6	97.7	94.3	N/A	N/A	96.6	,
7A1A4	155	169	100.0	95.9	45.0 🛕	25	60.0 🛕	98.2 •	N/A	97.0	98.8	95.9	N/A	N/A	93.5	
A1AU	120	143	100.0	98.6	54.5	15	100.0	92.3	N/A	96.5	97.9	95.8	N/A	N/A	92.3	
outh Wales	1,630	1,512	99.8	96.3	33.5	209	89.5	95.5	N/A	98.5	99.0	97.8	N/A	N/A	90.4	25
A2AJ	41	41	100.0	97.6	41.5	4	75.0	100.0	N/A	97.6	97.6	95.1	N/A	N/A	63.4	
'A2AL	182	156	100.0	92.9	44.2	26	96.2	100.0	N/A	100.0	100.0	100.0	N/A	N/A	91.0	
A2BL	95	63	100.0	90.5	23.8	7	85.7	100.0	N/A	92.1	100.0	92.1	N/A	N/A	84.1	
'A3B7	102	113	99.1	97.3	39.8	10	90.0	94.7 •	N/A	97.3	97.3	96.5	N/A	N/A	84.1 🛕	
'A3C4	116	83	100.0	94.0	18.1	7	57.1 🛕	100.0	N/A	98.8	100.0	98.8	N/A	N/A	89.2	
'A3C7	135	99	99.0	93.9	21.2	13	100.0	98.0	N/A	98.0	94.9	94.9	N/A	N/A	92.9	
'A3CJ	73	63	100.0	95.2	55.6	11	81.8	100.0	N/A	100.0	98.4	98.4	N/A	N/A	90.5	
A4C1	349	278	100.0	98.2	36.0 🛕	39	92.3	92.8	N/A	100.0	100.0	100.0	N/A	N/A	97.8	
A5B1	116	142	100.0	96.5	23.9 🛕	22	100.0	97.9 •	N/A	97.9	100.0	97.9	N/A	N/A	90.8	
A5B3	97	127	100.0	100.0	26.8	19	94.7	100.0	N/A	100.0	100.0	100.0	N/A	N/A	92.1	
A6AM	123	107	100.0	100.0	40.2	17	100.0	100.0	N/A	100.0	100.0	100.0	N/A	N/A	95.3	
A6AR	201	240	99.6	95.4	32.9	34	73.5 🛕	84.6	N/A	97.1	97.9	95.0	N/A	N/A	86.7	
Vales Total	2,089	1,999	99.8	96.3	36.5	275	88.4	95.5	N/A	98.1	98.8	97.2	N/A	N/A	91.3	26
England and Vales Total	30,647	32,502	99.0	97.5	89.5	4,460	66.1 🛕	92.5	N/A	92.9	93.7	88.8	N/A	N/A	91.8	59
ast year's results	(excluding Mesoth	elioma)														
2012 England and Wales Total	30,647	33,035	98.8	97.5	84.3 🛕	4,387	63.4 🛕	88.7 •	79.8	91.5	93.9	87.8			91.3	
Difference	0	-533	0.2	0.1	5.2	73	2.8	3.8	10.1	1.3	-0.2	0.9			0.5	
Counts aggregated	d by place first seen	trust.	1							\ 					<u> </u>	
ange Network																
lin			95.2	86.2	33.5		43.0	86.3	80.8	83.8	85.9	77.3		17.1	87.9	
Q			99.0	96.3	79.8		60.1	89.9	85.7	91.6	93.0	87.2		55.8	90.5	
1edian			99.6	98.9	92.3		67.7	92.9	90.3	92.9	94.5	89.2		73.3	91.7	
IQ			99.8	99.8	99.1		80.4	95.6	94.9	96.0	97.2	92.4		92.0	93.4	
1ax			100.0	99.9	100.0		89.5	99.7	99.2	99.5	99.0	97.8		94.2	96.9	
ana Turat																
lange Trust Min			79.0	0.0	0.0		0.0	6.4	5.3	56.9	18.8	18.3		0.0	62.0	
Q			99.2	98.6	94.4		48.9	90.2	85.2	90.2	92.5	83.6		22.2	89.4	
1edian			100.0	100.0	99.4		78.9	97.6	95.3	97.0	96.9	94.3		82.4	92.9	
Q			100.0	100.0	100.0		92.5	100.0	98.9	99.4	98.9	97.8		100.0	95.8	
Max			100.0	100.0	100.0		100.0	100.0	100.0	100.0	100.0	100.0		100.0	100.0	
Mean .			99.0	97.6	88.8		66.6	92.1	89.7	93.1	93.6	88.9		63.5	91.6	

10

Indicator	Definition	A	_	•
Expected number	Agreed expected number of cases	<50%	50-75%	>=75%
Actual number	Number of cases with date first seen in year specified	<95%		>=95%
MDT Completeness (%)	Complete when MDT Discussion Indicator is Y or N (denominator = all cases)	<85%		>=85%
CT Scan Field Completed (%)	Complete when CT Scan is Y or N (denominator = all cases)	<85%		>=85%
Bronchoscopy Field Completed (%)	Complete when Bronchoscopy is 1, 2, 3 or N (denominator = all cases)			
PS0-1 NSCLC Stage IA, IB, IIA or IIB	Number of NSCLC cases with Performance Status 0 or 1 and TNM Stage IA, IB, IIA or IIB	<75%		>=75%
% PS0-1 Stage IA, IB, IIA or IIB NSCLC having FEV1 absolute and % predicted	Complete when both FEV1 Percentage and FEV1 Absolute Amount are present (denominator = NSCLC cases with Performance Status 0 or 1 and TNM Stage IA, IB, IIA or IIB)	<85%		>=85%
Data Completeness Seen by Nurse Specialist (%)	Complete when Patient Assessed by a Lung Cancer Nurse Specialist is Y or N (denominator = all cases)	<85%		>=85%
Data Completeness Nurse Specialist present at Diagnosis (%)	Complete when Lung Cancer Nurse Specialist Present When Received Diagnosis is Y or N or Patient Assessed by a Lung Cancer Nurse Specialist = N (denominator = all English cases)			
Performance Status Completeness (%)	Complete when Performance status is present (excluding Not Recorded (5)) (denominator = all cases)	<85%		>=85%
Stage Completeness (%)	Complete when stage can be derived from the following fields: 1) Final pre-treatment TNM category 2) Pathological TNM category 3) Site Specific Stage Classification (excluding Unknown (X)) 4) Post Treatment Site-Specific Stage Classification (excluding Unknown (X)) (denominator = all cases)	<85%		>=85%
PS and Stage Completeness (%)	Complete when Performance Status and Stage are both complete (as defined above) (denominator = all cases)	<85%		>=85%
Number of patients where Co-morbidity precluded treatment	Number of patients where Reason Patient Did Not Receive First Choice Treatment = 3 (Co-morbidity precluding treatment)			
Comorbidity recorded where Co-morbidity precluded treatment (%)	Complete when Y present in any of the 6 Co-morbidity fields (Dementia/Cerebrovascular Disease, Cardiovascular Disease, Renal Failure, Other Malignancy, Severe Weight Loss or Other Significant Co-morbidity) (denominator = cases where Reason Patient Did Not Receive First Choice Treatment = 3 (Co-morbidity precluding treatment)).	<85%		>=85%
	Note that results are only reported where the organisation has >0 cases in the denominator.			
Treatment Recorded (%)	Complete when date present for Brachytherapy, Anti-cancer drug regimen, Surgery, Teletherapy, Palliative or Active Monitoring (denominator = all cases)	<85%		>=85%
Organisational Audit Participation (%)	Complete when organisation took part in and provided data for the latest organsational audit survey. Network and National figures are the percentage of trusts within the group that took part, excluding non-tertiary trusts with small activity numbers.			
	Organisation participated in survey, completing at least one data field			
	Organisation participated in survey, completing no data fields			
	▲ Organisation did not participate in survey			

Data completeness for key fields Scotland (2013)

Code	Expected number	Actual number	MDT Completeness (%)	CT Scan Field Completed (%)	Bronchoscopy Field Completed (%)	PS0-1 NSCLC Stage IA, IB, IIA or IIB	% PSO-1 NSCLC Stage IA, IB, IIA or IIB having FEV1 absolute and % predicted	Data Completeness Seen by Nurse Specialist (%)	Performance Status Completeness (%)	Stage Completeness (%)	PS and Stage Completeness (%)	Treatment Recorded (%)
SCAN	1,322	1,189	100.0	100.0	100.0	184	N/A	99.9	96.4	98.4	96.2	100.0
Borders	97	77	100.0	100.0	100.0	16	N/A N/A		100.0		100.0	100.0
Dumfries and Galloway	139	102	100.0	100.0	100.0	7	N/A N/A		85.3		83.3	100.0
Fife	328	300	100.0	100.0	100.0	41	N/A		97.7		97.7	100.0
Lothian	758	710	100.0	100.0	100.0	120	N/A N/A		97.0		97.0	100.0
Lourian	736	710	100.0	100.0	100.0	120	IN/A	100.0	97.0	70.0	97.0	100.0
WoSCAN	2,636	2,589	99.5	99.7	99.8	459	N/A	90.7	94.6	95.6	90.3	99.7
Ayrshire and Arran	343	391	99.7	100.0	99.7	42	N/A	99.0	98.5	98.2	96.7	99.2
Clyde	379	366	99.2	100.0	99.7	52	N/A	78.7	96.2	96.4	92.6	100.0
Forth Valley	255	224	100.0	100.0	100.0	42	N/A	99.1	93.8	94.2	87.9	100.0
Lanarkshire	535	521	99.4	99.2	99.8	141	N/A	92.7	91.9	98.3	90.2	99.8
North Glasgow	1,124	720	99.7	99.7	99.9	114	N/A	88.6	94.3	92.8	87.1	99.6
South Glasgow		367	99.2	99.7	100.0	68	N/A	89.9	94.0	94.8	88.8	100.0
		1										
NoSCAN	1,064	957	99.4	99.7	100.0	110	N/A		96.8		93.1	95.2
Grampian	400	371	100.0	100.0	100.0	42	N/A		94.3	90.8	87.3	100.0
Orkney	3	0					N/A					
Shetland	10	13	100.0	100.0	100.0	0	N/A		69.2		69.2	100.0
Highland	209	214	100.0	100.0	100.0	31	N/A		100.0		96.7	99.5
Argyll and Clyde (H)	31	27	100.0	100.0	100.0	5	N/A		96.3		96.3	100.0
Western Isles	9	12	100.0	100.0	100.0	1	N/A		100.0		100.0	100.0
Tayside	402	320	98.1	99.1	100.0	31	N/A	99.4	98.4	99.4	97.8	85.9
Scotland total	5,022	4,735	99.6	99.8	99.9	753	N/A	94.8	95.5	96.3	92.3	98.9
Last year's results (includ	ing mesothelioma)											
2012 Scotland Total	5,162	4,810	99.9	100.0	99.9	N/A	N/A	98.9	95.5	93.9		99.8
Difference	-140	-75	-0.3	-0.2	0.0	N/A	N/A	-4.1	0.0	2.4		-0.9
Counts aggregated by pla	ce first seen health board.											
Range Health Board												
Min			98.1	99.1	99.7			75.0	69.2	90.8	69.2	85.9
LQ			99.6	99.9	100.0			92.0	94.0		87.8	99.8
Median			100.0	100.0	100.0			99.3	96.3		94.5	100.0
UQ			100.0	100.0	100.0			100.0	98.4	99.6	97.2	100.0
Max			100.0	100.0	100.0			100.0	100.0		100.0	100.0

Indicator	Definition
Expected number	Agreed expected number of cases
Actual number	Number of cases with date first seen in year specified (excluding mesothelioma)
MDT Completeness (%)	Complete when MDT Discussion Indicator is Y or N (denominator = all cases, excluding mesothelioma
CT Scan Field Completed (%)	Complete when CT Scan is Y or N (denominator = all cases, excluding mesothelioma)
Bronchoscopy Field Completed (%)	Complete when Bronchoscopy is 1, 2, 3 or N (denominator = all cases, excluding mesothelioma)
PS0-1 NSCLC Stage IA, IB, IIA or IIB	Number of NSCLC cases with Performance Status 0 or 1 and TNM Stage IA, IB, IIA or IIB
% PS0-1 NSCLC Stage IA, IB, IIA or IIB having FEV1 absolute and % predicted	Complete when both FEV1 Percentage and FEV1 Absolute Amount are present (denominator = NSCLC cases with Performance Status 0 or 1 and TNM Stage IA, IB, IIA or IIB)
Data Completeness Seen by Nurse Specialist (%)	Complete when Patient Assessed by a Lung Cancer Nurse Specialist is Y or N (denominator = all cases, excluding mesothelioma)
Performance Status Completeness (%)	Complete when Performance status is present (excluding Not Recorded (5)) (denominator = all cases, excluding mesothelioma)
Stage Completeness (%)	Complete when stage can be derived from the following fields: 1) Final pre-treatment TNM category 2) Pathological TNM category 3) Site Specific Stage Classification (excluding Unknown (X)) 4) Post Treatment Site-Specific Stage Classification (excluding Unknown (X)) (denominator = all cases, excluding mesothelioma)
PS and Stage Completeness (%)	Complete when Performance Status and Stage are both complete (as defined above) (denominator = all cases, excluding mesothelioma, excluding mesothelioma)
Treatment Recorded (%)	Complete when date present for Brachytherapy, Anti-cancer drug regimen, Surgery, Teletherapy, Palliative or Active Monitoring (denominator = all cases, excluding mesothelioma)